Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

BioSpace

Hello, and welcome to BioSpace's The Weekly. I'm your host, Jeff Axt. Today we've got a range of industry updates for you from some much-needed good news for Amylyx and Definium's positive readout for anxiety. That's for its LSD-based psychedelic therapy. And then we've got some not-so-great news, some concerns about Ivan Eskibab survival benefits and a spate of deaths among patients treated with Neurocrin's approved Prader-Willi drug.

Plus, we'll end the show with a little bit of a discussion about Eli Lilly and how it is cracking down on the black market for its next-generation weight-loss asset, Ritatratide. Let's get started. Hi, guys. How are you doing? Hey. We finally have all four of us. It's good to see you all together again. I know. We're all back. The whole team. Get to be here. Before Italy leaves on her PTO. Yes, but I will be here for the podcast next week, so I'm just temporarily leaving.

I know you're coming back for the podcast. And then Gabby's out as well for a week, I think. September. It is just the tail end of all the summer vacations. I hope you had a great break last week, Heather. I did, yeah. It was awesome to see them. It was my best friend and her seven-year-old daughter. came to visit. And seven-year-olds are kind of hurricanes a little bit. You guys, Jeff and Natalie, obviously know this.

But, yeah, it was like, yeah, they just, the hurricane blew in and it blew out on Friday. And then I spent kind of the rest of the weekend sleeping. Recovering. Yeah. I can confirm that a six-year-old is also a hurricane and a three-year-old. Yeah, I thought they were either six or seven, so.

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.